ABCL
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
AbCellera Biologics Inc. (ABCL) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D). The rating has held at C+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.7) | D (1.3) | C+ (2.6) | B (3.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-10 | C+ (2.6) | D (1.3) | C+ (2.6) | A- (4.1) | C+ (2.6) | C+ (2.6) |
| 2026-11-03 | C+ (2.7) | D (1.2) | C+ (2.6) | A+ (5.0) | C+ (2.7) | C+ (2.8) |
| 2026-10-27 | C+ (2.7) | D (1.2) | C+ (2.7) | A+ (4.9) | C+ (2.6) | C+ (2.8) |
| 2026-10-20 | C+ (2.7) | D (1.2) | C+ (2.7) | A+ (4.9) | C+ (2.6) | C+ (2.8) |